8-KMaterial AgreementsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Dec 28, 2004)

Filed December 28, 2004For Securities:ALNY

Summary

This 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) on December 28, 2004, primarily reports on a material definitive agreement related to executive compensation. Specifically, the Compensation Committee of the Board of Directors granted a stock option to the President and CEO, Dr. John M. Maraganore, for 250,000 shares of common stock at an exercise price of $7.47 per share. This stock option grant is subject to vesting upon the attainment of a corporate goal, which will be determined by the Compensation Committee. The filing also includes the form of the nonstatutory stock option agreement as an exhibit, which is standard practice for stock incentive plans. Investors should note that this filing does not contain significant financial updates or operational developments, but rather focuses on executive equity incentives, which can be an indicator of management's alignment with shareholder interests.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. granted a stock option to its President and CEO, Dr. John M. Maraganore.
  • 2The option is for 250,000 shares of common stock.
  • 3The exercise price for the option is $7.47 per share.
  • 4The stock option is granted under the company's 2004 Stock Incentive Plan.
  • 5Vesting of the option is contingent upon the achievement of a corporate goal, to be determined by the Compensation Committee.
  • 6The filing includes the form of the nonstatutory stock option agreement as an exhibit.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report the entry into a material definitive agreement, specifically the granting of a stock option to Alnylam's CEO.

The CEO was granted an option to purchase up to 250,000 shares of common stock at an exercise price of $7.47 per share. The option's vesting is tied to the achievement of a corporate goal determined by the Compensation Committee.

No, this filing does not contain any financial statements or significant operational updates. It is solely focused on the executive stock option grant and related documentation.

The granting of stock options to executive leadership can align management's interests with those of shareholders, as the CEO's potential financial gain is linked to the company's performance and stock value. The vesting condition also indicates a focus on achieving specific corporate objectives.